Go here for resources and information about Cell Penetrating Peptides (CPPs)Available CPPs:
P1-fusion CPPs (protein domains):
P1
(Antennapedia-derived Penetratin-1; control peptide)
P1-RhoA (23-40) (see Immunity and Nature Immunology articles)
(Inhibition for steric hindrance of RhoA effector domain encompassing aa 23-40
P1-RhoA (75-92) (see Immunity and Nature Immunology articles)
(Inhibition for steric hindrance of RhoA effector domain encompassing aa 75-92)
P1-RhoA (92-119) (see Immunity and Nature Immunology articles)
(Inhibition for steric hindrance of RhoA effector domain encompassing aa 92-119
P1-PLD1 (944–962) (see Immunity and Nature Immunology articles)
(Inhibition for steric hindrance of PLD1 interaction with and activation by RhoA)
P1- PTPRG_WD (see Journal of Immunology article)
(PTPRG wedge domain - PTPRG activation) (see diagram and cristal structure)
P1- PTPRG_SCR (see Journal of Immunology article)
(PTPRG wedge domain scrambled)
P1-PTPRZ1 _WD
(PTPRZ1 wedge domain - PTPRZ1 activation)
P1-TKIP (see JCB article)
(JAK2 pesudosubstare blocking peptide)
P1-KIR
(JAK2 inhibitory peptide)
P1-PIP5K1C/Talin1
(PIP5K1C / Talin1 interaction domain)
TAT-fusion CPPs (full length fusion signaling proteins):
TAT peptide
(HIV-derived TAT control peptide)
TAT-eGFP
(Enhanced Green Fluorescent Protein)
TAT-Rac1 WT (see Immunity and Nature Immunology articles)
(Wilde-type Rac1)
TAT-Rac1 SN17 (see Immunity and Nature Immunology articles)
(Dominant-negative Rac1 mutant)
TAT-Rac1 Q61L (see PLoS One article)
(Dominant- positive Rac1 mutant)
TAT-Rac1 Q61LY40C (see PLoS One article)
(Dominant- positive Rac1 double mutant)
TAT-Rac1 Q61LF37A (see PLoS One article)
(Dominant- positive Rac1 double mutant)
TAT- CDC42WT (see Immunity and Nature Immunology articles)
(Wilde-type CDC42)
TAT- CDC42S17N (see Immunity and Nature Immunology articles)
(Dominant-negative CDC42 mutant)
TAT- CDC42Q61L (see Nature Medicine article)
(Dominant-positive CDC42 mutant)
TAT- CDC42G12V (see Nature Medicine article)
(Dominant- positive CDC42 mutant)
TAT- CDC42Q61LY40C (see Nature Medicine article)
(Dominant- positive CDC42 double mutant)
TAT- CDC42Q61LF37A (see Nature Medicine article)
(Dominant- positive CDC42 double mutant)
TAT-RhoC WT
(Wilde-type RhoC)
TAT-RhoC S17N
(Dominant-negative RhoC mutant)
TAT-RhoC G14V
(Dominant-positive RhoC mutant)
TAT-Rap1A WT
(Wilde-type Rap1A)
TAT-Rap1A S17N
(Dominant-negative Rap1A mutant)
TAT-Rap1A G12V
(Dominant-positive Rap1A mutant)
TAT-RhoA WT
(Wilde-type RhoA)
TAT-RhoA T19N
(Dominant-negative RhoA mutant)
TAT-RhoA G14V
(Dominant-positive RhoA mutant)
TAT-PLD1 K898R
(PLD1 lipase defective)
TAT-H-Ras WT
(Wilde-type H-Ras)
TAT-H-Ras S17N
(Dominant-negative H-Ras mutant)
TAT-H-Ras G12V
(Dominant-positive H-Ras mutant)
TAT-R-Ras S34N
(Dominant-negative R-Ras mutant)
TAT- PTPRG_ICD (see Journal of Immunology article)
(PTPRG intracellular tyrosine phosphatase domains D1+D2) (see diagram and cristal structure)
TAT- PTPRG_D1028A (see Journal of Immunology article)
(PTPRG intracellular tyrosine phosphatase-defective domains D1+D2)